Hypocrisy of the west
A legitimate tool to meet any public health crisis, rich countries, particularly the US, have resolutely opposed its deployment by developing …
High Court notice to Novartis on Cipla appeal
Cipla has challenged the court order restraining it from manufacturing generic version of respiratory ailment drug
SC rejects Bayer's appeal against compulsory licence for Nexavar
Indian pharma company, NATCO, can continue manufacturing generic version of liver and kidney cancer drug
A victory and a retreat on CLs
Supreme Court upholds India's first compulsory licence but government baulks at giving the second
Who is really afraid of the TRIPS agreement?
India has not shown the grit to fully use the inbuilt flexibilities in the WTO’s TRIPS pact to protect public health
Activists demand compulsory licence for another life-saving cancer drug
Appellate board's order upholding Natco's CL for sorafenib tosylate may pave way for manufacture of generic version of other patented drugs
The natco-pfizer test
Natco’s demand for a voluntary licence from Pfizer will establish how well the compulsory licence process works in India
Drug affordability test
Natco’s bid for a compulsory licence to manufacture a Bayer anti-cancer drug is a test of the law’s ‘reasonable price’ …
Testing the CL route
Roche’s Herceptin will be a test case for government and generics industry as India readies to issue compulsory licences for life-saving drugs
Will appellate body uphold grant of compulsory licence to cancer drug?
Hearing on Bayer's appeal against manufacture of generic version of Nexavar to conclude this week
Standing up to the US
India does not have to be apologetic about its patents law, which is fully compliant with WTO requirements on intellectual property protection